top of page

Tracking recent β-thal and CALD gene therapy launches with bluebird’s CEO

Andrew Obenshain describes key metrics bluebird is seeing early in the launch of two of its gene therapies on its Q2 earnings day.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page